Record #24119
Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor–Positive Metastatic Breast Cancer: ALTERNATIVE
Original paper date
Dec 15, 2017
Original DOI
Country
Institution
Open access
No
Article type
Notes from Retraction Watch
see also: https://ascopubs.org/doi/abs/10.1200/JCO.20.01894;
Citation lifecycle
How this paper is being cited
Pre-retraction
81
Same day
1
Post-retraction
167
% post-retraction
192.0%
~30.2 citations/yr before retraction · ~27.5 citations/yr after
— citing papers
Who is still citing this work
Loading…